Werner Cautreels is leaving Selecta, handing reins to Bayer vet; Novartis lines up a manufacturing partner for China CAR-T marketing
→ Werner Cautreels, the longtime CEO at Selecta Biosciences $SELB, is retiring from his post. The biotech reported this morning that Bayer vet Carsten Brunn has been named as the new CEO. Cautreels is staying on as an adviser after he leaves his job at the end of this year. Selecta is prepping a Phase III study for SEL-212, an experimental gout drug. Cautreels was named CEO in 2010, a couple of years after the launch of the company focused on Synthetic Vaccine Particle tech from the lab of MIT’s Bob Langer.
→ Novartis $NVS has found a manufacturing partner in China for its CAR-T drug Kymriah. Novartis is paying $40 million for a chunk of stock in Cellular Biomedicine Group $CBMG, which will take the lead on manufacturing the therapy while Novartis steers ahead on distribution, regulatory and commercialization efforts in China. “Together with Novartis, we hope to bring the first CAR-T cell therapy to patients in China,” says CBMG CEO Tony Liu. “In addition, we continue to focus on developing CBMG’s pipeline of immuno-oncology assets.”
→ The Dutch company A-Mansia Biotech raised an €18 million Series A financing round to back its research into the microbiome. Its founding scientists are Professor Willem de Vos from Wageningen University and Professor Patrice D. Cani from the University of Louvain.
→ Mérieux Equity Partners has lined up the launch of its Mérieux Participations 3 fund, with an initial $235 million to invest. Partners will be on the lookout for small- to mid-cap equity investments in a range of companies in healthcare and nutrition.